Metabolex, Inc, a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced the initiation of a research collaboration with Takeda San Francisco, Inc (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Metabolex will collaborate with TSF on the evaluation and validation of protein targets for the development of biological products. Metabolex will provide novel protein targets discovered through the use of Metabolex's target discovery technologies. Financial terms of the collaboration were not disclosed.

Harold Van Wart, president and chief executive officer of Metabolex said, "We are very excited about this partnership with TSF, Takeda's center of excellence for antibody research. The collaboration brings together Metabolex's expertise in diabetes and metabolic disease targets with TSF's deep strength in antibody drug discovery and non-clinical development."

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes.